Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: GlobeNewswire
PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported fourth quarter 2025 financial results. “We ended 2025 with encouraging data from our lead oncology program in ICI-refractory patients, an area of unmet medical need, that informed the initiation of our accelerated development plan for PLN-101095,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “In addition to oncology and the early-stage pipeline programs emerging from Pliant's proprietary integrin platform, we continue to assess opportunities to expand our clinical-stag
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
News
- Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual MeetingGlobeNewswire
- Pliant Therapeutics (PLRX) had its price target lowered by Canaccord Genuity Group Inc. from $4.00 to $3.00. They now have a "hold" rating on the stock.MarketBeat
- Pliant Therapeutics (PLRX) had its "overweight" rating reaffirmed by Piper Sandler.MarketBeat
- Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
PLRX
Earnings
- 3/11/26 - Beat
PLRX
Analyst Actions
- 3/13/26 - Canaccord Genuity
PLRX
Sec Filings
- 3/11/26 - Form S-8
- 3/11/26 - Form 8-K
- 3/11/26 - Form 10-K
- PLRX's page on the SEC website